Similar articles

• Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy.

  Jaime-Pérez JC, Rodríguez-Romo LN, González-Llano O, Chapa-Rodríguez A, Gómez-Almaguer D. Jaime-Pérez JC, et al. Br J Haematol. 2009 Mar;144(5):794-5. doi: 10.1111/j.1365-2141.2008.07497.x. Epub 2008 Nov 19. Br J Haematol. 2009. PMID: 19036096 No abstract available.
• Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

  Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Thomas DA, et al. Cancer. 2006 Apr 1;106(7):1569-80. doi: 10.1002/cncr.21776. Cancer. 2006. PMID: 16502413 Clinical Trial.
• New antibodies for acute lymphocytic leukemia.

  Advani AS. Advani AS. Clin Adv Hematol Oncol. 2014 Aug;12(8):547-9. Clin Adv Hematol Oncol. 2014. PMID: 25356581 No abstract available.
• Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.

  Thomas DA, O'Brien S, Kantarjian HM. Thomas DA, et al. Hematol Oncol Clin North Am. 2009 Oct;23(5):949-71, v. doi: 10.1016/j.hoc.2009.07.005. Hematol Oncol Clin North Am. 2009. PMID: 19825447 Free PMC article. Review.
• Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.

  Kantarjian H, Thomas D, Wayne AS, O'Brien S. Kantarjian H, et al. J Clin Oncol. 2012 Nov 1;30(31):3876-83. doi: 10.1200/JCO.2012.41.6768. Epub 2012 Aug 13. J Clin Oncol. 2012. PMID: 22891271 Free PMC article. Review. No abstract available.